SANA vs. IMCR, GLPG, AGIO, TWST, IDYA, TARS, CNTA, RXRX, INDV, and APGE
Should you be buying Sana Biotechnology stock or one of its competitors? The main competitors of Sana Biotechnology include Immunocore (IMCR), Galapagos (GLPG), Agios Pharmaceuticals (AGIO), Twist Bioscience (TWST), IDEAYA Biosciences (IDYA), Tarsus Pharmaceuticals (TARS), Centessa Pharmaceuticals (CNTA), Recursion Pharmaceuticals (RXRX), Indivior (INDV), and Apogee Therapeutics (APGE). These companies are all part of the "pharmaceutical products" industry.
Sana Biotechnology vs.
Immunocore (NASDAQ:IMCR) and Sana Biotechnology (NASDAQ:SANA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, community ranking, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.
Sana Biotechnology has a net margin of 0.00% compared to Immunocore's net margin of -15.87%. Immunocore's return on equity of -12.84% beat Sana Biotechnology's return on equity.
Immunocore currently has a consensus price target of $58.89, suggesting a potential upside of 63.90%. Sana Biotechnology has a consensus price target of $10.80, suggesting a potential upside of 271.13%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe Sana Biotechnology is more favorable than Immunocore.
In the previous week, Immunocore had 1 more articles in the media than Sana Biotechnology. MarketBeat recorded 9 mentions for Immunocore and 8 mentions for Sana Biotechnology. Immunocore's average media sentiment score of 1.11 beat Sana Biotechnology's score of 1.04 indicating that Immunocore is being referred to more favorably in the media.
Immunocore received 51 more outperform votes than Sana Biotechnology when rated by MarketBeat users. Likewise, 73.53% of users gave Immunocore an outperform vote while only 63.16% of users gave Sana Biotechnology an outperform vote.
Immunocore has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Sana Biotechnology has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500.
Immunocore has higher revenue and earnings than Sana Biotechnology. Immunocore is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.
84.5% of Immunocore shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 10.4% of Immunocore shares are held by company insiders. Comparatively, 30.1% of Sana Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Immunocore beats Sana Biotechnology on 10 of the 17 factors compared between the two stocks.
Get Sana Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for SANA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sana Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:SANA) was last updated on 6/11/2025 by MarketBeat.com Staff
